College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China.
Department of Nuclear Medicine, Pakistan Institute of Nuclear Medicine (PINUM) Cancer Hospital, Faisalabad, 38000, Punjab, Pakistan.
Appl Biochem Biotechnol. 2022 Jun;194(6):2672-2683. doi: 10.1007/s12010-022-03856-1. Epub 2022 Mar 3.
The accurate and early diagnosis of infection is an important feature in the biomedical sciences for better treatment and to decrease the rate of morbidity associated with diseases. Doxycycline (DC) is a semisynthetic antibiotic that belongs to tetracycline family and usually prescribed to treat a variety of infections. The objective of the present research work was to develop a new radiopharmaceutical Tc-Doxycycline (Tc-DC), by using SnCl·2HO as a reducing agent for diagnostic applications. It was confirmed through this study that Tc-DC possessed high radiolabeling yield (95%). In vitro studies were performed by incubating Tc-DC in human serum at 37 °C. The in vitro binding interaction of the labeled antibiotic was analyzed with bacterial strain (live Staphylococcus aureus cells), and its stability was further determined. Moreover, for in vivo infection imaging study, the infection was induced with S. aureus (gram positive) cells intramuscularly injected in mice models followed by biodistribution studies for Tc-DC that were performed. Biodistribution studies of Tc-DC showed that the radiotracer was significantly accumulated at the site of infection and indicated the renal route of excretion. Scintigraphic images obtained as a result of in vivo study showed good uptake of prepared radiotracer (Tc-DC) in the infectious lesions at 1-, 4-, and 24-h post-injection. Target-to-non-target ratios for Tc-DC were significantly different for the infectious lesions and non-infected tissues and remained 2.13 ± 0.3 up to 24-h post-injection of Tc-DC. Tc-DC showed preferential binding to living bacterial infected sites as compared to other parts of the body, and thus it can be inferred that Tc-DC might be a potential candidate to diagnose the infection.
准确和早期的感染诊断是生物医学科学的一个重要特征,有助于更好地治疗疾病并降低与疾病相关的发病率。强力霉素(DC)是一种半合成抗生素,属于四环素类,通常用于治疗各种感染。本研究工作的目的是开发一种新的放射性药物 Tc-强力霉素(Tc-DC),使用 SnCl·2HO 作为还原剂用于诊断应用。通过这项研究证实,Tc-DC 具有高放射性标记产率(95%)。通过在 37°C 下在人血清中孵育 Tc-DC 进行体外研究。通过与细菌菌株(活金黄色葡萄球菌细胞)分析标记抗生素的体外结合相互作用,并进一步确定其稳定性。此外,对于体内感染成像研究,通过将金黄色葡萄球菌(革兰氏阳性)细胞肌肉内注射到小鼠模型中诱导感染,然后进行 Tc-DC 的生物分布研究。Tc-DC 的生物分布研究表明,放射性示踪剂在感染部位明显积聚,并表明其排泄途径为肾脏。体内研究获得的闪烁成像显示,在注射后 1、4 和 24 小时,制备的放射性示踪剂(Tc-DC)在感染病变部位的摄取良好。Tc-DC 的靶标与非靶标比值对于感染病变和未感染组织差异显著,在注射 Tc-DC 后 24 小时仍保持 2.13±0.3。与身体的其他部位相比,Tc-DC 优先结合活的细菌感染部位,因此可以推断 Tc-DC 可能是诊断感染的潜在候选药物。